Why CPH investors should care about The HighBrid Lab
Finfeed
Archived
Jun 24, 2021
Following much shareholder speculation, Bruce Linton, strategic advisor for Creso Pharma (ASX: CPH), spoke to The Dales Report to explain the reasoning behind the merger decision and the multitude of opportunities the merger uncovers.